Aligos Therapeutics Inc. Common Stock (ALGS)

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsi…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

82

Website

www.aligos.com/

Fundamentals

1-day range

$6.7$7.09

Market cap

$34.10M

P/E (trailing)

—

P/E (forward)

-1.36

EPS (trailing)

$-8.70

Dividend yield

—

Beta

2.48

Avg. volume

181.7K

Forecasts

7 analyst ratings

Aligos Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALGS

  Aligos Therapeutics Inc. Common Stock

  $6.93

  ▼ 1.98%
  Market cap $34.10MP/E —
  $3.98$13.69
• ESLA

  Estrella Immunopharma Inc. Common Stock

  $0.705

  ▼ 2.10%
  Market cap $32.10MP/E —
  $0.6781$3.15
• DYAI

  Dyadic International Inc. Common Stock

  $0.6207

  ▼ 3.02%
  Market cap $37.17MP/E —
• ELUT

  Elutia Inc. Class A Common Stock

  $0.885

  ▲ 0.57%
  Market cap $38.95MP/E 0.75
  $0.5$2.4
• TVGN

  Tevogen Inc. Common Stock

  $6.89

  ▲ 2.07%
  Market cap $41.58MP/E —
  $3.64$49.5
• EVAX

  Evaxion A/S American Depositary Share

  $3.03

  ▼ 3.81%
  Market cap $24.98MP/E —
  $2.52$12.15
• MGX

  Metagenomi Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $46.68MP/E —
  $1.13$3.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
  Yahoo · 8/12/2026
• Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
  Benzinga · 8/12/2026
• Keep an eye on the top gainers and losers in Monday's session.
  ChartMill · 8/10/2026
• 12 Health Care Stocks Moving In Monday's Intraday Session
  Benzinga · 8/10/2026
• Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
  Yahoo · 8/6/2026
• Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
  Benzinga · 8/6/2026

• Symons Julian A. · March 9, 2026 · Grant

  23.3K
• Aneja Nikhil · March 9, 2026 · Grant

  9.4K
• Calhoun Lesley Ann · March 9, 2026 · Grant

  37.5K
• BLATT LAWRENCE · March 9, 2026 · Grant

  105.8K

Institutional Ownership

March 31, 2026

Total shares held

2.75M

Total value held

$20.40M

Institutional holders

31